Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.
We analyze the genomic profile of egg donors in different endometrial priming protocols,
compared with natural cycle, including the conventional single long acting GnRH agonist
injection in the mid luteal phase of the previous cycle of the endometrial priming and the
single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular
phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing
hormone
- 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.
Interventional
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
genetic endometrial human profile expression
implantation related genes profile expression
Oocyte donors will be followed up for four to six months
Yes
Carmen Vidal, MDphD
Principal Investigator
IVI Valencia
Spain: Spanish Agency of Medicines
VLC18012013
NCT01778452
November 2009
January 2013
Name | Location |
---|